lipoxin a4 has been researched along with Chronic Kidney Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Debska-Slizien, A; Drozd, A; Kaczkan, M; Malgorzewicz, S; Marlicz, W; Palma, J; Rutkowski, P; Stachowska, E; Szczuko, M | 1 |
| Bernis, C; de Sequera, P; Fernández-Juarez, G; García de Vinuesa, S; Goicoechea, M; Luño, J; Morales, E; Ortiz, A; Quiroga, B; Sanchez-Niño, MD; Verdalles, U; Verde, E | 1 |
1 trial(s) available for lipoxin a4 and Chronic Kidney Diseases
| Article | Year |
|---|---|
Low dose aspirin increases 15-epi-lipoxin A4 levels in diabetic chronic kidney disease patients.
Topics: Aged; Anti-Inflammatory Agents; Aspirin; Female; Glomerular Filtration Rate; Humans; Lipoxins; Male; Middle Aged; Renal Insufficiency, Chronic | 2017 |
1 other study(ies) available for lipoxin a4 and Chronic Kidney Diseases
| Article | Year |
|---|---|
Lipoxin (LTX A4 5S, 6R, 15R) levels drastically decrease after 5 years of hemodialysis treatment.
Topics: Aged; Biomarkers; Case-Control Studies; Down-Regulation; Female; Humans; Lipoxins; Male; Middle Aged; Poland; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome | 2020 |